Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).


Clinical Trial Description

Treatment:

Once patients are diagnosed with grade II~IV acute GVHD, the combination therapy should be initiated as soon as possible.

1. Methylprednisolone: 2mg/kg/d, iv or iv gtt, in two or three divided doses. Taper steroid every one or two weeks according to patient's response.

2. Ruxolitinib 5~10mg bid po for at least 28 days. If patient's ANC<0.5×10e9/L or PLT< 20×10e9/L, cease ruxolitinib until recovery of ANC higher than 0.5×10e9/L or PLT higher than 20×10e9/L.

Indication for stopping Ruxolitinib treatment:

1. No response after ruxolitinib treatment for 28 days.

2. Develop life-threatening complication.

3. ANC<0.5×10e9/L or PLT< 20×10e9/L.

Indication for second line acute GVHD treatment:

1. deterioration of acute GVHD in 3 days

2. no response after 7 days

3. no complete remission after 2 weeks.

Suggestions of second line therapy:

Basiliximab 20mg, d1, d4, d8. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03701698
Study type Interventional
Source Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact Liping Wan, M.D.
Phone 86-21-37798987
Email lipingwan@sjtu.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date November 1, 2018
Completion date October 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT02806947 - A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501) Phase 2
Completed NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia N/A
Terminated NCT01530256 - Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) Phase 1/Phase 2
Recruiting NCT04373057 - Prebiotic Galacto-oligosaccharide and Acute GVHD Phase 1/Phase 2
Completed NCT04645667 - Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Completed NCT00350181 - Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT Phase 2
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Recruiting NCT05263999 - A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Phase 3